Stocklytics Platform
Asset logo for symbol CYBN
Cybin
CYBN55
$11.00arrow_drop_up4.71%$0.49
High Growth
Asset logo for symbol CYBN
CYBN55

$11.00

arrow_drop_up4.71%

Performance History

Chart placeholder
Key Stats
Open$12.28
Prev. Close$12.00
EPS-5.46
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$233.91M
PE Ratio-
LOWHIGH
Day Range11.16
12.25
52 Week Range6.50
28.04
Ratios
Revenue-
EBITDA Margin %-
EPS-5.46

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Cybin (CYBN)

Cybin Inc. (CYBN) is a leading biotechnology company focused on developing psychedelic medicines to improve mental health and overall well-being. With a mission to revolutionize mental healthcare, Cybin is committed to harnessing the therapeutic potential of psychedelics to address a wide range of mental health disorders. The company is dedicated to conducting rigorous scientific research and clinical trials to establish the safety and efficacy of its psychedelic compounds.
As of the latest stock price history, CYBN has shown significant growth and investor interest. The stock has seen a steady increase in value, reflecting the market's recognition of the potential of psychedelic medicines. This positive trend is supported by the latest stock news, which highlights Cybin's advancements in research and partnerships with leading academic institutions and clinical experts.
Sector
Healthcare
Industry
Biotechnology
CEO
Headquarters
Toronto
Employees
50
Exchange
NYSE
add Cybin to watchlist

Keep an eye on Cybin

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Cybin's (CYBN) price per share?

The current price per share for Cybin (CYBN) is $11. The stock has seen a price change of $0.49 recently, indicating a 4.71% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Cybin (CYBN)?

For Cybin (CYBN), the 52-week high is $28.04, which is 154.95% from the current price. The 52-week low is $6.5, the current price is 69.23% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Cybin (CYBN) a growth stock?

Cybin (CYBN) has shown an average price growth of -3.55% over the past three years. It has received a score of 99 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cybin as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Cybin (CYBN) stock price performance year to date (YTD)?

As of the latest data, Cybin (CYBN) has a year-to-date price change of -27.63%. Over the past month, the stock has experienced a price change of 12.02%. Over the last three months, the change has been 9.32%. Over the past six months, the figure is -15.83%.
help

Is Cybin (CYBN) a profitable company?

Cybin (CYBN) has a net income of -$78.08M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$78.84M. Furthermore, the EBITDA is -$61.59M.
help

What is the market capitalization of Cybin (CYBN)?

Cybin (CYBN) has a market capitalization of $214.64M. The average daily trading volume is 10.99, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level